Shares of Lupin Ltd were trading in the red and 2% lower on 3 February despite the company’s manufacturing unit in New Jersey clearing USFDA inspection with zero observations.
The US Food and Drug Administration (USFDA) conducted a pre-approval inspection at the manufacturing facility in Somerset, New Jersey, for the Edaravone Oral Suspension, 105 mg/ 5 mL. The inspection was conducted between 28 January and 1 February, concluding by issuing Form 483 with zero observations.
The company’s board of directors will convene on 11 February 2025 to review and approve the unaudited standalone and consolidated financial results for the quarter and nine-month period ending 31 December 2024.
In January 2025, the company received an Establishment Inspection Report (EIR) from the USFDA for its Pithampur Unit-1 manufacturing facility, which produces both APIs and finished formulations.
Additionally, on 30 December 2024, the pharmaceutical giant strengthened its diabetes portfolio by acquiring the Huminsulin brand in India from Eli Lilly.
At 11:29 am, the shares of Lupin were trading 2.37% lower at Rs 2,007.50 on NSE.
Discover the next big investment! Unicorn Signals’ IPO screener helps you identify promising initial public offerings. Download Unicorn Signals and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!